Please upgrade your browser.
Support the Kidney Cancer Association by shopping smile.amazon.com. When you do, a percentage of your purchase will be donated to support our charity's mission.
"All drugs have risks and benefits," noted lead researcher Dr. Ming Hui Chen, an assistant professor of medicine at Harvard Medical School...
His insights tell the story of more than a great sports legend, but that of a man with the strength of character to face kidney cancer head on and beat it in 1998.
Priority is anti-tumor effects. Everything else, however severe, is considered the price worth paying.
Dr Michele Teng, who led the study, said if they results were replicated in humans it could lead to widespread changes in oncology practices
Pfizer and Merck KGaA have moved closer to bringing the fourth checkpoint inhibitor to the US market after the FDA granted a priority review for the drug in a rare form of skin cancer.
Examination of the TCGA RNA-seq dataset also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples.
...these approaches allow oncologists to examine tissue samples and learn more about how these drugs affect the primary tumor - See more at: http://www.onclive.com/onclive-tv/dr-margulis-on-different-approaches-to-adjuvant-therapy-in-rcc#sthash.RO7Md4Zh.dpuf
The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer...
Italian researchers found that people whose diets are rich in onions, garlic, and other alliums have a much lower risk of several types of cancer than those who avoid the pungent herbs.
|Powered by NeonCRM|